Literature DB >> 17058859

[Middle molecules removal. Beyond beta2-microglobulin].

F Maduell1, J J Sánchez-Canel, J A Blasco, V Navarro, A Ríus, E Torregrosa, M T Pin, C Cruz, J A Ferrero.   

Abstract

The uremic toxin removal capacity mainly depends on dialyzer and hemodialysis modes. The low-flux hemodialysis only removes solutes having molecular weights less than 5.000 Da. High-flux hemodyalisis represents a form of low-volume hemodiafiltration because of the internal filtration and back-filtration that can take place within a dialyzer. Hemodiafiltration with large volumes of replacement fluid seems to be the best technique for removing all small, medium-sized and large molecules. The objective of our study was to evaluate the large molecules removal bigger than beta2-microglobuline on high flux haemodialysis and on-line hemodiafiltration with postdilutional infusion, in patients with three times a week dialysis and on short daily dialysis. We studied 24 patients, 15 males and 9 females stable on haemodialysis programme, twelve on standard four to five hours three times a week dialysis and twelve on 2 to 2 1/2 hours six times a week dialysis. All patients were dialysed with Fresenius 4008 monitor, three sessions on high flux haemodialysis (HD) and three sessions on on-line hemodiafiltration (OL-HDF). Two sessions with each filter were performed (polisulfone HF80, polyethersulfone Arylane H9 and new polisulfone APS 900). Pre and postdialysis concentrations of urea, creatinine, (beta2-microglobulin (beta2-m), myoglobin, prolactin and alpha1 microglobulin (alpha1-m) were measured. There was no difference in urea and creatinine small molecules removal. beta2m removal was 68% on HD and 81% on OL-HDF. Myoglobin and prolactin present a similar removal pattern, a higher removal with new filters (60% with Arylane and 59% with APS) in comparison with clasical polisulfone (22% with HF80). The mean alpha1-m reduction rate on HD was 6% and on OL-HDF 22%. OL-HDF with APS 900 filter was the most remove technique (35.4%), significatively higher than the other modes and filters. We can conclude that the new filters generation reach a better uremic toxins removal, specially in large molecules higher than beta2-m and on HD modality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17058859

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  5 in total

Review 1.  Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yu-Hui Hung; Tai-Shuan Lai; Mohamed Belmouaz; Ya-Chun Tu; Chun-Fu Lai; Shuei-Liong Lin; Yung-Ming Chen
Journal:  Membranes (Basel)       Date:  2022-04-20

2.  Effect of different dialysis modalities on microinflammatory status and endothelial damage.

Authors:  Ana Merino; José Portolés; Rafael Selgas; Raquel Ojeda; Paula Buendia; Javier Ocaña; M Auxiliadora Bajo; Gloria del Peso; Julia Carracedo; Rafael Ramírez; Alejandro Martín-Malo; Pedro Aljama
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

3.  The Use of Coupled Plasma Filtration Adsorption in Traumatic Rhabdomyolysis.

Authors:  Mario Pezzi; Silvia Renda; Anna Maria Giglio; Anna Maria Scozzafava; Simona Paola Tiburzi; Patrizia Casella; Fabrizio Iannelli; Mario Verre
Journal:  Case Rep Crit Care       Date:  2017-03-19

4.  High-Flux Hemodialysis Benefits Hemodialysis Patients by Reducing Serum FGF-23 Levels and Reducing Vascular Calcification.

Authors:  Xiao Fu; Qin-Qin Cui; Jian-Ping Ning; Shuang-Shuang Fu; Xiao-Hua Liao
Journal:  Med Sci Monit       Date:  2015-11-11

5.  Measuring serum beta2-microglobulin to predict long-term mortality in hemodialysis patients using low-flux dialyzer reuse.

Authors:  Nguyen Huu Dung; Nguyen Trung Kien; Nguyen Thi Thu Hai; Phan The Cuong; Nguyen Thi Thu Huong; Dao Bui Quy Quyen; Nguyen Minh Tuan; Do Manh Ha; Truong Quy Kien; Nguyen Thi Thuy Dung; Pham Quoc Toan; Hoang Trung Vinh; Tomoko Usui; Le Viet Thang
Journal:  Ther Clin Risk Manag       Date:  2019-07-09       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.